FDA Accepts BLA for Alvotech's Entyvio Biosimilar (AVT16)
ALVO sits 42% above its 52-week low of $2.94 on elevated volume (4.1× avg).
Summary
Alvotech's Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio, has been accepted by the FDA for review, marking a significant regulatory milestone.
Key Events · Product Development and Regulatory · ALVO
-
FDA Accepts BLA for AVT16
The FDA has accepted Alvotech's Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab), moving it closer to potential approval and commercialization under its partnership with Teva.
-
Q1 2026 Financial Statements Furnished
The filing includes the full unaudited Q1 2026 financial statements, which were previously announced on May 6, 2026. The company reported a profit of $1.0 million, a significant decrease from $109.7 million in Q1 2025, and experienced substantial cash burn.
-
Prior BLA Resubmissions Noted
The filing reiterates the resubmission of Biologics License Applications for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar) to the FDA on June 4, 2026, which was previously disclosed in a separate 6-K filing.
Analysis · ALVO · Life Sciences
This filing announces the FDA's acceptance of Alvotech's Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio. This is a critical step towards potential market approval and commercialization of a key pipeline asset, especially given Alvotech's recent regulatory challenges and ongoing need for new revenue streams. The filing also includes the full Q1 2026 financial statements and reiterates the recent resubmission of BLAs for AVT05 and AVT06, but these were previously announced or filed.
At the time of this filing, ALVO was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.94 to $10.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.